Related Experiment Videos
The development of hemoglobin solutions as red cell substitutes: hemoglobin solutions
S A Gould1, L R Sehgal, H L Sehgal
1Department of Surgery, Michael Reese Hospital and Medical Center, Chicago University of Illinois, College of Medicine 60201, USA.
Transfusion Science
|February 7, 1995
Summary
Polymerized pyridoxylated hemoglobin solution (Poly SFH-P) offers a safer alternative to previous hemoglobin-based oxygen carriers. This new formulation minimizes toxicity, showing promise as a red cell substitute for trauma and surgery patients.
Area of Science:
- Biomedical Engineering
- Hematology
- Toxicology
Background:
- Hemoglobin-based oxygen carriers (HBOCs) show efficacy but suffer from significant toxicity, including renal dysfunction and vasoconstriction.
- These toxicities are linked to tetrameric hemoglobin extravasation and interaction with endothelial-derived relaxing factor.
- Previous chemical modifications of tetrameric hemoglobin have not fully resolved extravasation issues.
Purpose of the Study:
- To develop and characterize a novel polymerized hemoglobin solution (Poly SFH-P) with minimal free tetrameric hemoglobin.
- To address the toxicity concerns associated with earlier HBOCs.
- To evaluate Poly SFH-P as a potential red cell substitute for clinical applications.
Main Methods:
- Development of a polymerized hemoglobin solution (Poly SFH-P) designed to minimize unreacted tetramer.
- Characterization of the Poly SFH-P formulation.
- Clinical trials in volunteers to assess safety and efficacy.
Main Results:
- Poly SFH-P is a polymerized hemoglobin solution virtually free of unreacted tetramer.
- Successful completion of clinical trials in volunteers.
- Ongoing trials to assess safety and efficacy in treating acute blood loss.
Conclusions:
- Poly SFH-P represents a significant advancement in HBOC development, overcoming limitations of previous formulations.
- The minimized tetramer content in Poly SFH-P is expected to reduce toxicity.
- Poly SFH-P shows potential as a safe and effective red cell substitute for managing acute blood loss in clinical settings.